Vitreoretinopathy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: VTR007 MIFTS: 49	Vitreoretinopathy Categories: Eye diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Vitreoretinopathy

MalaCards integrated aliases for Vitreoretinopathy:

Name: Vitreoretinopathy ⁵⁸ ²⁸ ⁵ ⁷⁵

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare eye diseases

External Ids:

Orphanet ⁵⁸ ORPHA98668

Sources

Summaries for Vitreoretinopathy

MalaCards based summary: Vitreoretinopathy is related to vitreoretinopathy, neovascular inflammatory and exudative vitreoretinopathy 1. An important gene associated with Vitreoretinopathy is TSPAN12 (Tetraspanin 12), and among its related pathways/superpathways are ERK Signaling and Nanog in Mammalian ESC Pluripotency. The drugs Triamcinolone and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone marrow, and related phenotypes are nervous system and embryo

Sources

Related Diseases for Vitreoretinopathy

Diseases in the Vitreoretinopathy family:

Vcan-Related Vitreoretinopathy

Diseases related to Vitreoretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 406)

#	Related Disease	Score	Top Affiliating Genes
1	vitreoretinopathy, neovascular inflammatory	32.8	VEGFA TGFB1 CAPN5
2	exudative vitreoretinopathy 1	31.2	ZNF408 VEGFA TSPAN12 TNF NDP LRP5
3	exudative vitreoretinopathy	31.1	ZNF408 VEGFA TSPAN12 NDP LRP5 FZD4
4	retinal perforation	30.7	VEGFA COL2A1 CAPN5
5	macular holes	30.6	VEGFA IL6 ABCA4
6	uveitis	30.5	VEGFA TNF IL6 CAPN5
7	neovascular glaucoma	30.5	VEGFA IL6 CAPN5
8	rubeosis iridis	30.4	VEGFA IL6
9	anterior uveitis	30.3	VEGFA TNF IL6
10	coats disease	30.3	ZNF408 VEGFA TSPAN12 NDP LRP5 FZD4
11	retinal vascular disease	30.2	ZNF408 VEGFA TSPAN12 TNF NDP IL6
12	telangiectasis	30.1	VEGFA TNF NDP
13	peripheral retinal degeneration	30.0	ZNF408 TSPAN12 COL2A1 ABCA4
14	endophthalmitis	30.0	VEGFA TNF IL6
15	autoimmune uveitis	30.0	TNF IL6 CAPN5
16	norrie disease	30.0	ZNF408 VEGFA TSPAN12 NDP LRP5 FZD4
17	macular retinal edema	30.0	VEGFA TNF IL6 ABCA4
18	leukocoria	30.0	ZNF408 TSPAN12 NDP LRP5 FZD4
19	retinal ischemia	29.9	VEGFA TNF IL6
20	persistent hyperplastic primary vitreous	29.9	ZNF408 VEGFA TSPAN12 NDP LRP5 FZD4
21	vitreoretinal dystrophy	29.9	ZNF408 TSPAN12 CAPN5
22	osteoporosis-pseudoglioma syndrome	29.9	NDP LRP5 FZD4 CTNNB1
23	posterior uveitis	29.8	VEGFA TNF IL6 CAPN5
24	strabismus	29.8	ZNF408 TSPAN12 FZD4 CTNNB1 COL2A1
25	panuveitis	29.8	VEGFA TNF IL6
26	corneal disease	29.7	VEGFA TNF IL6
27	macular dystrophy, dominant cystoid	29.7	VEGFA TNF IL6 CAPN5 ABCA4
28	vitreoretinal degeneration	29.7	TSPAN12 LRRC32 LRP5 ABCA4
29	acute retinal necrosis syndrome	29.6	VEGFA TNF IL6
30	chorioretinitis	29.6	VEGFA TNF IL6
31	retinal vein occlusion	29.6	VEGFA TNF IL6
32	chorioretinal scar	29.5	VEGFA ABCA4
33	retinal detachment	29.5	ZNF408 VEGFA TSPAN12 TNF TGFB1 NDP
34	refractive error	29.4	VEGFA COL2A1 ABCA4
35	arthropathy	29.4	TNF IL6 COL2A1
36	keratitis, hereditary	29.4	VEGFA TNF IL6
37	retinal telangiectasia	29.3	ZNF408 VEGFA TSPAN12 NDP LRP5 FZD4
38	osteoarthritis	29.2	TNF TGFB1 IL6 COL2A1
39	cataract	29.1	VEGFA VCAN TNF TGFB1 IL6 CTNNB1
40	toxoplasmosis	29.1	TNF TGFB1 IL6 ABCA4
41	glaucoma, primary open angle	29.0	VEGFA TNF ABCA4
42	eye disease	28.4	VEGFA TSPAN12 TNF NDP LRP5 IL6
43	connective tissue disease	28.4	VEGFA TNF TGFB1 IL6 CTNNB1 COL2A1
44	fundus dystrophy	28.3	ZNF408 VEGFA VCAN TSPAN12 LRP5 FZD4
45	osteoporosis	28.2	VEGFA TNF TGFB1 NDP LRP5 IL6
46	retinitis pigmentosa	27.9	ZNF408 VEGFA TSPAN12 TNF NDP IL6
47	wagner vitreoretinopathy	11.6
48	exudative vitreoretinopathy 4	11.6
49	exudative vitreoretinopathy 2, x-linked	11.6
50	exudative vitreoretinopathy 5	11.6

Graphical network of the top 20 diseases related to Vitreoretinopathy:

Sources

Symptoms & Phenotypes for Vitreoretinopathy

MGI Mouse Phenotypes related to Vitreoretinopathy:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.14	ABCA4 COL2A1 CTNNB1 FZD4 IL6 LRP5
2	embryo	MP:0005380	9.97	COL2A1 CTNNB1 FZD4 LRP5 TGFB1 TNF
3	cardiovascular system	MP:0005385	9.93	ABCA4 COL2A1 CTNNB1 FZD4 IL6 LRP5
4	digestive/alimentary	MP:0005381	9.92	COL2A1 CTNNB1 FZD4 IL6 LRRC32 TGFB1
5	pigmentation	MP:0001186	9.83	ABCA4 CTNNB1 FZD4 LRP5 NDP
6	craniofacial	MP:0005382	9.8	COL2A1 CTNNB1 LRP5 LRRC32 TGFB1 TNF
7	skeleton	MP:0005390	9.65	ABCA4 COL2A1 CTNNB1 IL6 LRP5 NDP
8	vision/eye	MP:0005391	9.36	ABCA4 COL2A1 CTNNB1 FZD4 IL6 LRP5

Sources

Drugs & Therapeutics for Vitreoretinopathy

Drugs for Vitreoretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Isotretinoin

Approved, Investigational, Nutraceutical

Phase 4

302-79-4, 4759-48-2

5538 444795 5282379

Immunosuppressive Agents

Phase 4

Dermatologic Agents

Phase 4

Immunologic Factors

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Triamcinolone hexacetonide

Phase 4

Triamcinolone diacetate

Phase 4

Triamcinolone Acetonide

Phase 4

6436

glucocorticoids

Phase 4

Anti-Inflammatory Agents

Phase 4

Anesthetics

Phase 4

Anesthetics, Local

Phase 4

Colchicine

Approved

Phase 3

64-86-8

2833 6167

Fluorouracil

Approved

Phase 3

51-21-8

3385

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 3

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 3

9041-08-1

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Antimetabolites

Phase 3

Fibrinolytic Agents

Phase 3

Anticoagulants

Phase 3

Calcium heparin

Phase 3

Heparin, Low-Molecular-Weight

Phase 3

Pharmaceutical Solutions

Phase 3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Infliximab

Approved

Phase 2

170277-31-3

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Bromfenac

Approved, Withdrawn

Phase 2

91714-94-2

60726

Antineoplastic Agents, Immunological

Phase 2

Angiogenesis Inhibitors

Phase 2

Antirheumatic Agents

Phase 2

topoisomerase I inhibitors

Phase 2

Analgesics

Phase 2

Anti-Inflammatory Agents, Non-Steroidal

Phase 2

Ophthalmic Solutions

Phase 2

Analgesics, Non-Narcotic

Phase 2

Levoleucovorin

Approved, Experimental, Investigational

Phase 1

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 1

1959-05-2, 59-05-2

4112 126941

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 1

59-30-3

6037

Folic Acid Antagonists

Phase 1

Folate

Phase 1

Vitamin B9

Phase 1

Vitamin B Complex

Phase 1

Dipivefrin

Approved

52365-63-6

3105

Racepinephrine

Approved, Vet_approved

Early Phase 1

51-43-4, 329-65-7

838 5816

Dexamethasone acetate

Approved, Investigational, Vet_approved

1177-87-3

3680

Interventional clinical trials:

(show all 32)

#	Name	Status	NCT ID	Phase	Drugs
1	Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy	Completed	NCT01445028	Phase 4	Isotretinoin
2	The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery	Completed	NCT01995045	Phase 4	Triamcinolone;Bupivicaine Hydrochloride
3	Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment	Unknown status	NCT00370201	Phase 3	colchicine
4	Repeated Intra-silicone Oil Injection of Methotrexate for Management of Proliferative Vitreoretinopathy Grade C; A Multi-center Study	Unknown status	NCT04482543	Phase 2, Phase 3	Methotrexate
5	Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)	Unknown status	NCT00370760	Phase 3	oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
6	The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR	Unknown status	NCT00371020	Phase 3	low molecular weight heparin, 5-FU
7	Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy	Completed	NCT00373282	Phase 3	Triamcinolone acetonide
8	The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferaivie Vitreoretinopathy	Completed	NCT04136366	Phase 3	ADX-2191 (intravitreal methotrexate 0.8%)
9	The Silicone Study	Completed	NCT00000140	Phase 3	Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
10	Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.	Completed	NCT02834559	Phase 3	5-fluorouracil and low molecular weight heparin;Placebo
11	Intravitreal Decorin Preventing Proliferative Vitreoretinopathy in Perforating Injuries: a Pilot Study.	Completed	NCT02865031	Phase 1, Phase 2	Decorin
12	Bevacizumab Against Recurrent Retinal Detachment	Completed	NCT02192970	Phase 2	Bevacizumab
13	A Multi-Center, Randomized, Sham-Controlled, Phase II Trial Evaluating Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Macula Off Rhegmatogenous Retinal Detachment Repair (The PREVENT-PVR Trial)	Recruiting	NCT04580147	Phase 2	Intravitreal aflibercept injection
14	Treatment of Proliferative Vitreoretinopathy With Intravitreal Infliximab	Recruiting	NCT04891991	Phase 2	Intravitreal infliximab
15	A Prospective Matched Cohort Study of Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment With Proliferative Vitreoretinopathy	Not yet recruiting	NCT05523869	Phase 2	Intravitreal topotecan
16	Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation	Not yet recruiting	NCT05107921	Phase 2	Bromfenac Sodium
17	A Phase I, Multicenter, Uncontrolled, Open Label Study Assessing the Efficacy and Safety of a Combination of Systemic and Intravitreal Injections of Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients With RheGmatogenous Retinal DetacHmenT (the SIGHT Study)	Not yet recruiting	NCT04830878	Phase 1	Methotrexate
18	Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics	Unknown status	NCT04682054
19	Evaluation Use Optical Coherence Tomography - Rescan During Dissection of Macular Membranes : Pre and Post Operative Aspects	Unknown status	NCT02748421
20	Perfluorocarbone Liquids for Tamponading Lower Retinal Breaks to Achieve Retinal Reattachment in Eyes of Retinal Detachment With Proliferative Vitreoretinopathy	Completed	NCT04168255
21	A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy	Completed	NCT01860586		Bevacizumab
22	An Observational Study of Retinal Function and Structure After Repair of Macula-involving Retinal Detachment Complicated by Proliferative Vitreoretinopathy (RDPVR) Using Adaptive Optics	Completed	NCT03551574
23	Familial Exudative Vitreoretinopathy Clinical and Molecular Studies	Completed	NCT00106756
24	Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy	Completed	NCT03208205
25	Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Retinal Detachment With Proliferative Vitreoretinopathy Using 3D Visualization System	Completed	NCT04490876
26	A Prospective, Randomized Study Comparing 1000 Centistoke and 5000 Centistoke Silicone Oil Tamponade for Repair of Proliferative Vitreoretinopathy Retinal Detachments and Diabetic Tractional Retinal Detachments	Completed	NCT01255293
27	Adrenocorticotropic Hormone for Intraocular Inflammation in Post-operative Proliferative Vitreoretinopathy Patients	Recruiting	NCT03727776	Early Phase 1	Adrenocorticotropic Hormone
28	Randomized Trial Comparing Air Versus Gas Tamponade in Primary Retinal Detachment	Recruiting	NCT05561569
29	Internal Limiting Membrane Peeling in Macula-off Retinal Detachment With Grade B Proliferative Vitreoretinopathy	Not yet recruiting	NCT05538156
30	Slow-Release Dexamethasone in Reducing Proliferative Vitreoretinopathy After Vitreotomy in Proliferative Diabetic Retinopathy	Not yet recruiting	NCT05415826
31	Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencing	Not yet recruiting	NCT04520789
32	The Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (DEXTENZA) in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia. (TENDER)	Not yet recruiting	NCT05620901	Early Phase 1	Dextenza 0.4Mg Ophthalmic Insert;Pred Forte

Search NIH Clinical Center for Vitreoretinopathy

Sources

Genetic Tests for Vitreoretinopathy

Genetic tests related to Vitreoretinopathy:

#	Genetic test	Affiliating Genes
1	Vitreoretinopathy ²⁸

Sources

Anatomical Context for Vitreoretinopathy

Organs/tissues related to Vitreoretinopathy:

MalaCards : Eye, Retina, Bone Marrow, Endothelial, Smooth Muscle, Monocytes, Cortex

Sources

Publications for Vitreoretinopathy

Articles related to Vitreoretinopathy:

(show top 50) (show all 3542)

#	Title	Authors	PMID	Year
1	Molecular genetic analysis using targeted NGS analysis of 677 individuals with retinal dystrophy. ⁵	Jespersgaard C...Gronskov K	30718709	2019
2	A comprehensive functional analysis on the pathogenesis of novel TSPAN12 and NDP variants in familial exudative vitreoretinopathy. ⁶²	Zhao R...Li S	36453149	2022
3	Clinical characteristics and mutation spectrum in 33 Chinese families with familial exudative vitreoretinopathy. ⁶²	Mao J...Shen L	36411543	2022
4	DRAINAGE RETINOTOMY IS A RISK FACTOR FOR SURGICAL FAILURE AFTER PARS PLANA VITRECTOMY IN PATIENTS WITH PRIMARY UNCOMPLICATED RHEGMATOGENOUS RETINAL DETACHMENT. ⁶²	Ohara H...Kiuchi Y	36394886	2022
5	Novel insights into the pathophysiology of proliferative vitreoretinopathy: The role of vitreoschisis-induced vitreous cortex remnants. ⁶²	van Overdam KA...Verdijk RM	35673878	2022
6	Idelalisib inhibits experimental proliferative vitroretinopathy. ⁶²	Dong L...Lei H	35854067	2022
7	Norcantharidin attenuates epidermal growth factor-induced proliferation, EMT and motility in ARPE-19 cells by modulating the AKT/snail/E-cadherin axis. ⁶²	Chien HW...Hsieh YH	36356893	2022
8	The intervention of epithelial-mesenchymal transition in homeostasis of human retinal pigment epithelial cells: a review. ⁶²	Gelat B...Gelat R	36377481	2022
9	Early-onset Neovascular Inflammatory Vitreoretinopathy Due to Two de Novo CAPN5 Mutations in Chinese Patients: A Case Series. ⁶²	Xia FJ...Zhao PQ	36369866	2022
10	Immune modulating nanoparticles for the treatment of ocular diseases. ⁶²	Fang L...Zhou H	36424630	2022
11	Outcomes of Zone 3 Open Globe Injuries By Wound Extent Subcategorization of zone 3 injuries segregates visual and anatomic outcomes. ⁶²	Bleicher ID...Armstrong GW	36332844	2022
12	Giant Retinal Tears: Long-Term Outcomes of Fellow Eyes. ⁶²	Sengillo JD...Giant Retinal Tear Study Group	36378614	2022
13	Outcomes of Using Perfluorocarbon Liquid as Postoperative Tamponade in Complex Inferior Retinal Detachments. ⁶²	Naz S...Rizvi SF	36377014	2022
14	Predictive values of systemic inflammation biomarkers in proliferative vitreoretinopathy associated with primary rhegmatogenous retinal detachment. ⁶²	Kocak N...Yeter V	36375137	2022
15	The outcomes of primary pars plana vitrectomy alone as a first surgical procedure in pediatric rhegmatogenous retinal detachment. ⁶²	Kemer Atik B...Artunay O	35570251	2022
16	Multimodal Retinal Imaging Findings in Two Cousins With VCAN-Related Vitreoretinopathy or Wagner Disease. ⁶²	Parra MM...Hartnett ME	36378611	2022
17	Signal Peptide Variants in Inherited Retinal Diseases: A Multi-Institutional Case Series. ⁶²	Jimenez HJ...Pulido JS	36362148	2022
18	Dual phenotype: co-occurring Leber congenital amaurosis and familial exudative vitreoretinopathy: a case report. ⁶²	Miraldi Utz V...Sisk RA	36426739	2022
19	A novel variant in the TSPAN12 gene-presenting as unilateral myopia, pediatric cataract, and heterochromia in a patient with familial exudative vitreoretinopathy. ⁶²	Elhusseiny AM...Alkharashi M	34151585	2022
20	Whole-Exome Sequencing Reveals Novel NDP Variants in X-Linked Familial Exudative Vitreoretinopathy. ⁶²	Peng Y...Yang M	35037517	2022
21	A novel splicing variant of VCAN identified in a Chinese family initially diagnosed with familial exudative vitreoretinopathy. ⁶²	Zhong J...Li Y	36333947	2022
22	PREVALENCE, CHARACTERISTICS, AND OUTCOMES OF RHEGMATOGENOUS RETINAL DETACHMENT IN EYES WITH TRABECULECTOMY OR GLAUCOMA DRAINAGE DEVICES. ⁶²	Starr MR...Yonekawa Y	35963003	2022
23	PROLIFERATIVE RETINOPATHY IN A 13-YEAR-OLD WITH ADAMS-OLIVER SYNDROME. ⁶²	Meyer BI...Jain N	33323896	2022
24	Familial exudative vitreoretinopathy (FEVR) in a child with novel microarray-defined deletion of 11q14 previously diagnosed as retinopathy of prematurity (ROP). ⁶²	Lopez-Canizares A...Berrocal AM	36444989	2022
25	Genetic and clinical characteristics of 24 mainland Chinese patients with CTNNB1 loss-of-function variants. ⁶²	Yan D...Mainland Chinese League of NEDSDV Rare Disease	36153650	2022
26	Pars Plana Vitrectomy with and without Supplemental Scleral Buckle for the Repair of Rhegmatogenous Retinal Detachment: A Meta-analysis. ⁶²	Eshtiaghi A...Muni RH	35227949	2022
27	LRP5 BIALLELIC MUTATIONS CAUSE A HIGHER INCIDENCE OF SEVERE PHENOTYPE COMPARED WITH LRP5 MONOALLELIC MUTATION. ⁶²	Chen C...Zhao P	36018796	2022
28	COVID-19 Vaccination Hesitancy and Its Association With Altered Presentation of Primary Rhegmatogenous Retinal Detachment. ⁶²	Mundae R...Tang PH	35609676	2022
29	Outcomes of chronic macula-off retinal detachment repair. ⁶²	Milner DC...Manoharan N	36289075	2022
30	Localized versus 360-degree laser photocoagulation with limited pars plana vitrectomy in the management of primary rhegmatogenous retinal detachment. ⁶²	Ryoo NK...Park KH	36207689	2022
31	Intravitreal Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment: A Systematic Review. ⁶²	Balas M...Muni RH	36239680	2022
32	Preoperative and Postoperative Factors Affecting Functional Success in Anatomically Successful Retinal Detachment Surgery. ⁶²	Guner ME...Kir N	36220639	2022
33	A hybrid 26G needle drainage technique in scleral buckling: A mini scleral cut-down. ⁶²	Markan A...Singh R	36190054	2022
34	Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial. ⁶²	Schaub F...PRIVENT Study Group	35680097	2022
35	Mechanisms of Epithelial-Mesenchymal Transition and Prevention of Dispase-Induced PVR by Delivery of an Antioxidant αB Crystallin Peptide. ⁶²	Wada I...Kannan R	36290802	2022
36	Advances in Vitreoretinal Surgery. ⁶²	Ribeiro L...Maia M	36362657	2022
37	Novel CTNNB1 variant leading to neurodevelopmental disorder with spastic diplegia and visual defects plus peripheral neuropathy: A case report. ⁶²	Spagnoli C...Fusco C	35880249	2022
38	Large inferior retinectomies for proliferative vitreoretinopathy in silicone oil-filled eyes. ⁶²	Barbosa GCS...Gomes AMV	36183118	2022
39	Emerging roles of circular RNAs in retinal diseases. ⁶²	Hanineva A...Zhang SX	35142661	2022
40	Intraoperative optical coherence tomography observation with perfluorocarbon tamponade for subretinal membranes in proliferative vitreous retinopathy. ⁶²	Shiraki A...Nishida K	36084328	2022
41	Risk Factors for Failure of Final Anatomic Surgical Reattachment in Retinal Detachments From Combat Ocular Trauma. ⁶²	Purt B...Colyer MH	36107623	2022
42	Outcomes of Heavy Silicone Oil (Densiron) compared to Silicone Oil in primary rhegmatogenous retinal detachment: a multivariable regression model. ⁶²	Moussa G...Andreatta W	36057670	2022
43	Systemic and Intraocular Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Children With Rhegmatogenous Retinal Detachment and Underlying Inflammatory Disease. ⁶²	Al-Moujahed A...Wood E	36380820	2022
44	Development of Proliferative Vitreoretinopathy Is Attenuated by Chicken Ovalbumin Upstream Promoter Transcriptional Factor 1 Via Inhibiting Epithelial-Mesenchymal Transition. ⁶²	Jin H...Yu J	36333112	2022
45	Severe Familial Exudative Vitreoretinopathy, Congenital Hearing Loss, and Developmental Delay in a Child With Biallelic Variants in FZD4. ⁶²	van der Ende SR...Robitaille JM	35951321	2022
46	Mutation spectrum in a cohort with familial exudative vitreoretinopathy. ⁶²	Qu N...Huang X	35876299	2022
47	Vitreoschisis and retinal detachment: New insight in proliferative vitreoretinopathy. ⁶²	Rizzo S...Caporossi T	34779683	2022
48	Long-term clinical prognosis of 335 infant single-gene positive FEVR cases. ⁶²	Chen C...Peng X	35918671	2022
49	Cystoid Macular Edema after Rhegmatogenous Retinal Detachment Repair with Pars Plana Vitrectomy: Rate, Risk Factors, and Outcomes. ⁶²	Merad M...Gabrielle PH	36013153	2022
50	Role of CFH Y402H and ARMS2 A69S polymorphisms in susceptibility to post rhegmatogenous retinal detachment macular complications. ⁶²	Aydinlou ZH...Soheilian M	35236246	2022

Sources

Genes for Vitreoretinopathy

Genes related to Vitreoretinopathy (2 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TSPAN12	Tetraspanin 12	Protein Coding	417.37	Pathogenic ⁵ GeneCards inferred via : Disorders Publications (show sections)
2	ABCA4	ATP Binding Cassette Subfamily A Member 4	Protein Coding	407.38	Pathogenic ⁵ GeneCards inferred via : Publications (show sections)	30718709
3	LRP5	LDL Receptor Related Protein 5	Protein Coding	61.98	Likely pathogenic ⁵ GeneCards inferred via : Disorders Publications Gene name Summaries (show sections)
4	NDP	Norrin Cystine Knot Growth Factor NDP	Protein Coding	37.09	GeneCards inferred via : Disorders Publications Gene name Summaries (show sections)
5	FZD4	Frizzled Class Receptor 4	Protein Coding	27.61	GeneCards inferred via : Disorders Publications Gene name (show sections)
6	ZNF408	Zinc Finger Protein 408	Protein Coding	25.59	GeneCards inferred via : Disorders Publications Summaries (show sections)
7	CAPN5	Calpain 5	Protein Coding	25.58	GeneCards inferred via : Disorders Publications Gene name (show sections)
8	LRRC32	Leucine Rich Repeat Containing 32	Protein Coding	25	Likely pathogenic ⁵
9	VCAN	Versican	Protein Coding	16.41	GeneCards inferred via : Disorders Publications (show sections)
10	EVR3	Exudative Vitreoretinopathy 3	Genetic Locus	16.25	GeneCards inferred via : Publications Gene name (show sections)
11	IGFBP6	Insulin Like Growth Factor Binding Protein 6	Protein Coding	16.21	GeneCards inferred via : Publications Summaries (show sections)
12	COL2A1	Collagen Type II Alpha 1 Chain	Protein Coding	15.94	GeneCards inferred via : Disorders Publications (show sections)
13	CTNNB1	Catenin Beta 1	Protein Coding	15.83	GeneCards inferred via : Disorders Publications (show sections)
14	IL6	Interleukin 6	Protein Coding	8.21	GeneCards inferred via : Publications (show sections)
15	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	7.98	GeneCards inferred via : Publications (show sections)
16	TGFB1	Transforming Growth Factor Beta 1	Protein Coding	7.94	GeneCards inferred via : Publications (show sections)
17	TNF	Tumor Necrosis Factor	Protein Coding	7.92	GeneCards inferred via : Publications (show sections)

Sources

Variations for Vitreoretinopathy

ClinVar genetic disease variations for Vitreoretinopathy:

⁵ (show top 50) (show all 235)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ABCA4	NM_000350.3(ABCA4):c.5908C>T (p.Leu1970Phe)	SNV	Pathogenic	7892	rs28938473	GRCh37: 1:94473287-94473287 GRCh38: 1:94007731-94007731
2	ABCA4	NM_000350.3(ABCA4):c.6089G>A (p.Arg2030Gln)	SNV	Pathogenic	99428	rs61750641	GRCh37: 1:94471055-94471055 GRCh38: 1:94005499-94005499
3	TSPAN12	NM_012338.4(TSPAN12):c.100del (p.Trp34fs)	DEL	Pathogenic	523501	rs1554403767	GRCh37: 7:120480130-120480130 GRCh38: 7:120840076-120840076
4	LRRC32	NM_001128922.2(LRRC32):c.1630C>T (p.Arg544Ter)	SNV	Likely Pathogenic	545640	rs369867819	GRCh37: 11:76371007-76371007 GRCh38: 11:76659963-76659963
5	LRP5	NM_002335.4(LRP5):c.2090A>G (p.Lys697Arg)	SNV	Likely Pathogenic	560373	rs1565083843	GRCh37: 11:68174280-68174280 GRCh38: 11:68406812-68406812
6	VCAN	NM_004385.5(VCAN):c.3673C>A (p.Pro1225Thr)	SNV	Uncertain Significance	903936	rs1746123738	GRCh37: 5:82817798-82817798 GRCh38: 5:83521979-83521979
7	CDH23	NM_022124.6(CDH23):c.7241A>T (p.Asp2414Val)	SNV	Uncertain Significance	636215	rs1589428738	GRCh37: 10:73559265-73559265 GRCh38: 10:71799508-71799508
8	CDH23, C10orf105	NM_022124.6(CDH23):c.3331G>T (p.Val1111Phe)	SNV	Uncertain Significance	636161	rs397517321	GRCh37: 10:73472532-73472532 GRCh38: 10:71712775-71712775
9	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.8058A>C (p.Leu2686Phe)	SNV	Uncertain Significance	354452	rs780717994	GRCh37: 5:82836880-82836880 GRCh38: 5:83541061-83541061
10	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.5482C>T (p.Pro1828Ser)	SNV	Uncertain Significance	354427	rs886060823	GRCh37: 5:82834304-82834304 GRCh38: 5:83538485-83538485
11	VCAN	NM_004385.5(VCAN):c.930G>A (p.Val310=)	SNV	Uncertain Significance	354394	rs886060818	GRCh37: 5:82808103-82808103 GRCh38: 5:83512284-83512284
12	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.7337C>T (p.Ala2446Val)	SNV	Uncertain Significance	906505	rs1561257553	GRCh37: 5:82836159-82836159 GRCh38: 5:83540340-83540340
13	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.6138A>G (p.Gly2046=)	SNV	Uncertain Significance	906460	rs1746854455	GRCh37: 5:82834960-82834960 GRCh38: 5:83539141-83539141
14	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.9494-9T>G	SNV	Uncertain Significance	904377	rs1747543997	GRCh37: 5:82849174-82849174 GRCh38: 5:83553355-83553355
15	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.7447C>G (p.Pro2483Ala)	SNV	Uncertain Significance	904189	rs1746926635	GRCh37: 5:82836269-82836269 GRCh38: 5:83540450-83540450
16	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.6727A>G (p.Thr2243Ala)	SNV	Uncertain Significance	904135	rs751656177	GRCh37: 5:82835549-82835549 GRCh38: 5:83539730-83539730
17	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.6704A>T (p.His2235Leu)	SNV	Uncertain Significance	904134	rs1746887068	GRCh37: 5:82835526-82835526 GRCh38: 5:83539707-83539707
18	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.4761T>A (p.Val1587=)	SNV	Uncertain Significance	904001	rs1746783267	GRCh37: 5:82833583-82833583 GRCh38: 5:83537764-83537764
19	VCAN	NM_004385.5(VCAN):c.2741G>A (p.Gly914Asp)	SNV	Uncertain Significance	903869	rs200429289	GRCh37: 5:82816866-82816866 GRCh38: 5:83521047-83521047
20	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.6201A>G (p.Glu2067=)	SNV	Uncertain Significance	354434	rs780184359	GRCh37: 5:82835023-82835023 GRCh38: 5:83539204-83539204
21	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.5427C>T (p.His1809=)	SNV	Uncertain Significance	354426	rs779803420	GRCh37: 5:82834249-82834249 GRCh38: 5:83538430-83538430
22	VCAN	NM_004385.5(VCAN):c.-259C>T	SNV	Uncertain Significance	354383	rs886060813	GRCh37: 5:82767590-82767590 GRCh38: 5:83471771-83471771
23	VCAN	NM_004385.5(VCAN):c.883_885del	DEL	Uncertain Significance	354481	rs886060832	GRCh37: 5:82877136-82877138 GRCh38: 5:83581317-83581319
24	VCAN	NM_004385.5(VCAN):c.*2C>T	SNV	Uncertain Significance	354468	rs370984795	GRCh37: 5:82876255-82876255 GRCh38: 5:83580436-83580436
25	VCAN	NM_004385.5(VCAN):c.3264A>G (p.Pro1088=)	SNV	Uncertain Significance	354417	rs767745674	GRCh37: 5:82817389-82817389 GRCh38: 5:83521570-83521570
26	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.8064C>T (p.Pro2688=)	SNV	Uncertain Significance	354454	rs886060827	GRCh37: 5:82836886-82836886 GRCh38: 5:83541067-83541067
27	VCAN	NM_004385.5(VCAN):c.*1091C>T	SNV	Uncertain Significance	354489	rs886060836	GRCh37: 5:82877344-82877344 GRCh38: 5:83581525-83581525
28	VCAN	NM_004385.5(VCAN):c.*625G>A	SNV	Uncertain Significance	907764	rs939870012	GRCh37: 5:82876878-82876878 GRCh38: 5:83581059-83581059
29	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.9403C>A (p.Pro3135Thr)	SNV	Uncertain Significance	907719	rs1747300004	GRCh37: 5:82843813-82843813 GRCh38: 5:83547994-83547994
30	VCAN	NM_004385.5(VCAN):c.1112C>T (p.Pro371Leu)	SNV	Uncertain Significance	906147	rs1745984120	GRCh37: 5:82815237-82815237 GRCh38: 5:83519418-83519418
31	VCAN	NM_004385.5(VCAN):c.3202G>A (p.Gly1068Ser)	SNV	Uncertain Significance	906273	rs1231605869	GRCh37: 5:82817327-82817327 GRCh38: 5:83521508-83521508
32	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.4292G>A (p.Arg1431His)	SNV	Uncertain Significance	906329	rs747887033	GRCh37: 5:82833114-82833114 GRCh38: 5:83537295-83537295
33	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.5201C>T (p.Thr1734Met)	SNV	Uncertain Significance	850338	rs200941140	GRCh37: 5:82834023-82834023 GRCh38: 5:83538204-83538204
34	VCAN	NM_004385.5(VCAN):c.881_883del	DEL	Uncertain Significance	354480	rs886060831	GRCh37: 5:82877134-82877136 GRCh38: 5:83581315-83581317
35	VCAN	NM_004385.4(VCAN):c.-334C>T	SNV	Uncertain Significance	354382	rs886060812	GRCh37: 5:82767515-82767515 GRCh38: 5:83471696-83471696
36	VCAN	NM_004385.5(VCAN):c.297G>C (p.Gly99=)	SNV	Uncertain Significance	354389	rs886060817	GRCh37: 5:82786143-82786143 GRCh38: 5:83490324-83490324
37	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.5836C>T (p.His1946Tyr)	SNV	Uncertain Significance	354431	rs886060825	GRCh37: 5:82834658-82834658 GRCh38: 5:83538839-83538839
38	VCAN	NM_004385.5(VCAN):c.3046A>G (p.Ile1016Val)	SNV	Uncertain Significance	905761	rs139937202	GRCh37: 5:82817171-82817171 GRCh38: 5:83521352-83521352
39	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.4022G>A (p.Ser1341Asn)	SNV	Uncertain Significance	905822	rs1746739066	GRCh37: 5:82832844-82832844 GRCh38: 5:83537025-83537025
40	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.4805C>A (p.Thr1602Asn)	SNV	Uncertain Significance	904002	rs1386946213	GRCh37: 5:82833627-82833627 GRCh38: 5:83537808-83537808
41	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.7434T>G (p.Thr2478=)	SNV	Uncertain Significance	907515	rs1746925822	GRCh37: 5:82836256-82836256 GRCh38: 5:83540437-83540437
42	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.8052C>T (p.Asp2684=)	SNV	Uncertain Significance	907575	rs184452501	GRCh37: 5:82836874-82836874 GRCh38: 5:83541055-83541055
43	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.4545C>T (p.Ala1515=)	SNV	Uncertain Significance	907335	rs1746771607	GRCh37: 5:82833367-82833367 GRCh38: 5:83537548-83537548
44	VCAN	NM_004385.5(VCAN):c.3340G>A (p.Val1114Met)	SNV	Uncertain Significance	903935	rs1746106150	GRCh37: 5:82817465-82817465 GRCh38: 5:83521646-83521646
45	VCAN	NM_004385.5(VCAN):c.375G>A (p.Ala125=)	SNV	Uncertain Significance	906080	rs762753715	GRCh37: 5:82786221-82786221 GRCh38: 5:83490402-83490402
46	VCAN	NM_004385.5(VCAN):c.*1753C>T	SNV	Uncertain Significance	906888	rs904583529	GRCh37: 5:82878006-82878006 GRCh38: 5:83582187-83582187
47	VCAN	NM_004385.5(VCAN):c.*1717C>T	SNV	Uncertain Significance	906887	rs537687030	GRCh37: 5:82877970-82877970 GRCh38: 5:83582151-83582151
48	VCAN	NM_004385.5(VCAN):c.1240G>A (p.Ala414Thr)	SNV	Uncertain Significance	907150	rs749795455	GRCh37: 5:82815365-82815365 GRCh38: 5:83519546-83519546
49	VCAN	NM_004385.5(VCAN):c.*93G>A	SNV	Uncertain Significance	906774	rs560274180	GRCh37: 5:82876346-82876346 GRCh38: 5:83580527-83580527
50	VCAN-AS1, VCAN	NM_004385.5(VCAN):c.9266-14C>T	SNV	Uncertain Significance	905111	rs1747170920	GRCh37: 5:82841342-82841342 GRCh38: 5:83545523-83545523

Sources

Expression for Vitreoretinopathy

Search GEO for disease gene expression data for Vitreoretinopathy.

Sources

Pathways for Vitreoretinopathy

Pathways related to Vitreoretinopathy according to GeneCards Suite gene sharing:

(show all 34)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.49	VEGFA VCAN TNF TGFB1 LRP5 IL6
2	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.18	VEGFA TNF TGFB1 IL6 FZD4 CTNNB1
3	Malignant pleural mesothelioma ⁷⁴	12.57	VEGFA TGFB1 LRP5 IL6 CTNNB1
4	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.06	CTNNB1 FZD4 LRP5 TGFB1
5	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.04	VEGFA TNF IL6 CTNNB1
6	MicroRNAs in cardiomyocyte hypertrophy ⁷⁴ Show member pathways Cardiac hypertrophic response ⁷⁴	11.99	TNF TGFB1 LRP5 CTNNB1
7	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	11.98	TGFB1 IL6 FZD4 CTNNB1
8	Adipogenesis ⁷⁴	11.91	TNF TGFB1 IL6 CTNNB1
9	TGF-beta receptor signaling in skeletal dysplasias ⁷⁴ Show member pathways TGF-beta receptor signaling ⁷⁴	11.9	TNF TGFB1 CTNNB1
10	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.83	TNF TGFB1 IL6
11	Allograft rejection ⁷⁴	11.79	VEGFA TNF TGFB1
12	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.77	VEGFA TNF TGFB1 IL6
13	Clock-controlled autophagy in bone metabolism ⁷⁴	11.72	TGFB1 LRP5 IL6
14	CCL18 signaling pathway ⁷⁴	11.69	VEGFA TGFB1 IL6 FZD4
15	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.67	TNF TGFB1 IL6
16	Primary focal segmental glomerulosclerosis (FSGS) ⁷⁴	11.66	CTNNB1 LRP5 TGFB1
17	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.65	COL2A1 IL6 TGFB1 VCAN
18	AP-1 transcription factor network ⁶¹	11.63	TGFB1 IL6 CTNNB1
19	Spinal cord injury ⁷⁴	11.61	VCAN TNF TGFB1 IL6 COL2A1
20	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.59	VEGFA TNF IL6
21	Osteoblast differentiation and related diseases ⁷⁴	11.58	LRP5 FZD4 CTNNB1
22	Lung fibrosis ⁷⁴	11.57	TNF TGFB1 IL6
23	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.54	TNF TGFB1 IL6
24	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.5	VEGFA TGFB1 IL6
25	Burn wound healing ⁷⁴	11.43	VEGFA TNF TGFB1 IL6
26	Pluripotent stem cell differentiation pathway ⁷⁴	11.42	VEGFA TGFB1 IL6
27	Colorectal Cancer Metastasis ⁶⁴	11.38	VEGFA TNF TGFB1 LRP5 IL6 FZD4
28	Cytokines and inflammatory response ⁷⁴	11.12	TNF TGFB1 IL6
29	Prostaglandin signaling ⁷⁴	11.08	VEGFA TNF IL6
30	G-protein signaling_Rap2B regulation pathway ²²	10.93	VCAN TNF TGFB1 IL6 COL2A1
31	RXR and RAR heterodimerization with other nuclear receptor ⁶¹	10.8	TNF TGFB1
32	IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	10.73	TGFB1 IL6
33	Immune infiltration in pancreatic cancer ⁷⁴	10.69	VEGFA TNF TGFB1 IL6
34	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.27	TNF IL6

Sources

GO Terms for Vitreoretinopathy

Cellular components related to Vitreoretinopathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.16	VEGFA VCAN TNF TGFB1 NDP LRRC32
2	cell surface	GO:0009986	9.8	CAPN5 FZD4 LRRC32 NDP TGFB1 TNF
3	extracellular matrix	GO:0031012	9.4	VEGFA VCAN TGFB1 NDP LRRC32 COL2A1

Biological processes related to Vitreoretinopathy according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of DNA-templated transcription	GO:0045893	10.34	CTNNB1 FZD4 IL6 LRP5 NDP TGFB1
2	positive regulation of gene expression	GO:0010628	10.29	VEGFA TNF TGFB1 LRRC32 IL6 CTNNB1
3	positive regulation of epithelial to mesenchymal transition	GO:0010718	10.04	TGFB1 IL6 CTNNB1
4	positive regulation of MAPK cascade	GO:0043410	10.02	CTNNB1 IGFBP6 IL6 TNF VEGFA
5	negative regulation of fat cell differentiation	GO:0045599	10.01	TNF TGFB1 IL6
6	chondrocyte differentiation	GO:0002062	10	TGFB1 CTNNB1 COL2A1
7	positive regulation of smooth muscle cell proliferation	GO:0048661	10	TNF TGFB1 IL6
8	positive regulation of protein-containing complex assembly	GO:0031334	9.99	VEGFA TNF TGFB1
9	regulation of angiogenesis	GO:0045765	9.95	TSPAN12 IL6 CTNNB1
10	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.95	VEGFA TNF TGFB1 IL6
11	osteoclast differentiation	GO:0030316	9.92	TNF TGFB1 CTNNB1
12	vascular endothelial growth factor production	GO:0010573	9.88	TNF IL6
13	vasculogenesis	GO:0001570	9.87	VEGFA TGFB1 FZD4 CTNNB1
14	retinal blood vessel morphogenesis	GO:0061304	9.86	FZD4 LRP5
15	liver regeneration	GO:0097421	9.85	TNF TGFB1 IL6
16	negative regulation of neurogenesis	GO:0050768	9.83	TNF IL6 CTNNB1
17	positive regulation of mononuclear cell migration	GO:0071677	9.72	TGFB1 TNF
18	positive regulation of receptor signaling pathway via STAT	GO:1904894	9.71	IL6 TGFB1
19	retina vasculature morphogenesis in camera-type eye	GO:0061299	9.65	NDP LRP5 FZD4
20	extracellular matrix-cell signaling	GO:0035426	9.63	FZD4 LRP5 NDP
21	positive regulation of miRNA maturation	GO:1903800	9.58	TGFB1 IL6
22	Norrin signaling pathway	GO:0110135	9.43	NDP LRP5 FZD4
23	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.4	TNF NDP LRP5 IL6 FZD4 CTNNB1